The Progress and Promise of iPSC-derived Therapies
Induced pluripotent stem cells (iPSCs) are a type of stem cell that can be generated directly from adult cells. The history and importance of iPSCs are significant in the field of regenerative medicine, biology, and the potential treatment of various diseases.
The development of iPSCs has revolutionized the field of stem cell research and has opened up new avenues for understanding human development, disease mechanisms, and the potential for cell-based therapies. However, there are still challenges to be addressed, such as ensuring the safety of iPSC-derived cells for clinical use, understanding the long-term effects of reprogramming, and developing efficient differentiation protocols. Despite these challenges, iPSCs remain a highly promising area of research with the potential to significantly impact medicine and human health.
Check out this video to learn about the history and application of iPSCs as well as the critical steps in an iPSC R&D workflow.
Explore More
Formulate and freeze aliquot supplies into cryocontainers.
Detailed and comprehensive characterization methods are needed to ensure patient safety including biosafety testing, genetic stability, pluripotency phenotype as well as cell viability and more.
Gently obtain final iPSC products with maintained biological characteristics.
Expand iPSCs utilizing growth factors and cytokines to achieve production culture volume and cell density as well as to maintain cell functionality through the cryopreservation process.
Establishes stem cell source to be used for multiple products. Perform extensive qualification and characterization testing.
Select the best clones that meet defined quality criteria and ability to differentiate into desired cell type.
Expand clonal cells utilizing growth factors and cytokines to obtain sufficient supply for research and development needs – while constantly checking for consistent marker expression.
Genome editing might be necessary in some cases to influence the histocompatibility profile of stem cells.
Select target cells using pluripotency markers. Evaluate and compare individual iPSCs for pluripotency and differentiation with advanced techniques to ensure the best lines are selected moving forward.
Reprogramming of somatic cells with different methods, such us Lentivirus, Retrovirus, Sendai virus, Episomal vectors etc. Use growth factors and cytokines to influence specific behaviors in cells.
Sourcing representative cells for reprogramming.
Measuring the pluripotency and viability of iPSCs to aid selection of the most appropriate cell line to use for differentiation.
Apply protocols using specific agents such as transcription factors, cytokines, and growth factors to induce differentiation into target cells.
iPSCs are created by introducing a set of specific genes, often called reprogramming factors, into adult cells. These factors reprogram the cells' DNA, turning them back into cells with pluripotent capabilities.
The main difference is their origin. Embryonic stem cells (ESCs) are derived from the inner cell mass of a blastocyst, an early-stage preimplantation embryo, while iPSCs are derived from adult somatic cells that have been genetically reprogrammed. Functionally, both cell types are similar in their pluripotent capabilities.
iPSCs are important because they offer a source of pluripotent cells that can be generated without the ethical concerns associated with the use of embryonic stem cells. They also allow for the creation of patient-specific cells, which can be used for personalized medicine, disease modeling, and drug testing.
iPSCs are still largely in the research and clinical trial phases for most applications. There have been some early clinical trials using iPSC-derived cells for conditions such as macular degeneration, Parkinson's disease, and heart disease, but widespread clinical use is still in the future.
Adult stem cells, such as hematopoietic stem cells found in bone marrow, are limited in the types of cells they can become. iPSCs, on the other hand, are pluripotent, which means they have the potential to differentiate into nearly any cell type in the body.
Yes, iPSCs can be generated from patients with genetic diseases, providing a powerful tool to study these diseases in the laboratory. Researchers can observe how the disease develops and progresses at the cellular level, which can lead to new insights and treatments.
The future of iPSC research is focused on improving the safety and efficiency of cell reprogramming, developing better methods for differentiating iPSCs into specific cell types, and advancing the use of iPSCs in clinical therapies. Additionally, combining iPSC technology with gene editing tools like CRISPR could lead to breakthroughs in treating genetic disorders.
Quantitative live-cell analysis for optimization of culture conditions and evaluation of cell health in human iPSC-derived neurons.
Combined iQue® advanced flow cytometry and Incucyte® live-cell analysis approach for evaluating iPSC pluripotency and differentiation.
Effectively use RUO growth factors & cytokines with iPSC media to preserve pluripotency, support growth & increase time between feedings.
Perform continuous, real-time morphological assessments for easy monitoring of iPSC colonies throughout differentiation.
Enables a gentle mechanical transfer method with high specificity maximizing cell viability and clonality while maintaining pluripotency.
Conserve precious samples and time during iPSC phenotyping by sampling as little as a single microliter from miniaturized assay volumes.
Explore our range of high-quality, animal-free research use only growth factors and cytokines for cell-based applications.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.